<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04451811</url>
  </required_header>
  <id_info>
    <org_study_id>OPL-002-102</org_study_id>
    <nct_id>NCT04451811</nct_id>
  </id_info>
  <brief_title>A PK Dose Proportionality Study of OPL-002 in Healthy Volunteers</brief_title>
  <official_title>A Pharmacokinetic Dose Proportionality Study of OPL-002 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oppilan Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oppilan Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, randomized, open-label, three-way crossover, single dose,
      pharmacokinetic dose proportionality study of oral OPL-002 in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 6, 2020</start_date>
  <completion_date type="Anticipated">July 25, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 25, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of OPL-002</measure>
    <time_frame>0 to 48 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality of 5 and 20 mg</measure>
    <time_frame>0 to 48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute lymphocyte count</measure>
    <time_frame>0 to 48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>OPL-002 SDD 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg SDD formulation of OPL-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPL-002 5 mg Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 mg tablet formulation of OPL-002</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OPL-002 20 mg Tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 mg tablet formulation of OPL-002</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OPL-002</intervention_name>
    <description>Spray dried dispersion and tablet formulation</description>
    <arm_group_label>OPL-002 20 mg Tablet</arm_group_label>
    <arm_group_label>OPL-002 5 mg Tablet</arm_group_label>
    <arm_group_label>OPL-002 SDD 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female (of non-childbearing potential only) between 18 and 55 years of age.

          -  Females must be of non-childbearing potential and must have undergone one of the
             following sterilization procedures, and have official documentation, at least 6 months
             prior to the first dose:

               1. hysteroscopic sterilization;

               2. bilateral tubal ligation or bilateral salpingectomy;

               3. hysterectomy;

               4. bilateral oophorectomy, or;

               5. be postmenopausal with amenorrhea for at least 1 year prior to the first dose and
                  have FSH serum levels consistent with postmenopausal status as per investigator
                  judgment.

          -  Male subjects must use reliable forms of contraception from screening to 30 days after
             the end of dosing.

          -  Good general health as determined by medical history, and by results of physical
             examination, vital signs, ECG, and clinical laboratory tests obtained within 28 days
             (4 weeks) prior to study drug administration.

        Exclusion Criteria:

          -  History or presence of any clinically significant organ system disease that could
             interfere with the objectives of the study or the safety of the subjects.

          -  pressure and heart rate are outside the ranges 90-140 mmHg systolic, 40-90 mmHg
             diastolic, heart rate 60-100 beats/min.

          -  12-lead ECG with any abnormality judged by the Investigator to be clinically
             significant, QRS &gt;= 110 milliseconds (msec), QT/QTcF interval of &gt; 450 msec for men or
             &gt;470 msec for women, or PR &gt; 200 msec.

          -  Presence or history of any abnormality or illness, which in the opinion of the
             Investigator may affect absorption, distribution, metabolism or elimination of the
             study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Gregg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Oppilan Pharma Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MiRa Huyghe</last_name>
    <phone>+1 858 212 1707</phone>
    <email>mhuyghe@oppilan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT9 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Close</last_name>
      <phone>+44 02890554013</phone>
      <email>laura.close@celerion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 25, 2020</study_first_submitted>
  <study_first_submitted_qc>June 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 30, 2020</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

